65 results about "Esophagus Carcinoma" patented technology

Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to globo H, SSEA3, and SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, skin, bone, lungs, breast, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervical, ovarian, and / or prostate cancer.

Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, lung, breast, mouse, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervix, ovary, and / or prostate cancer.

Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to globo H, SSEA3, and SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, skin, bone, lungs, breast, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervical, ovarian, and / or prostate cancer.

Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as breast cancer, lung cancer, esophageal cancer, rectal cancer, biliary cancer, liver cancer, buccal cancer, gastric cancer, colon cancer, nasopharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, neuroendocrine cancer, adrenal cancer, thyroid cancer, bone cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, and / or brain tumor.

The present invention provides antibodies useful as therapeutics for treating and / or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast Cancer, lung Cancer, gastric Cancer, ovarian Cancer, hepatocellular Cancer, colon Cancer, pancreatic Cancer, esophageal Cancer, head & neck Cancer, kidney Cancer, in particular renal cell Carcinoma, prostate Cancer, liver cancer, melanoma, sarcoma, myeloma, neuroblastoma, placental choriocarcinoma, cervical cancer, and thyroid Cancer, and the metastatic forms thereof. In one embodiment, the rumor disease is metastatic cancer in the lung.

The invention discloses an anti-tumor combination and the application thereof; the anti-tumor combination which includes effective dose of platinum-based chemotherapy and AKT inhibitor and / or p70S6K1 inhibitor has the function of inhibiting the drug resistance of the tumor to the platinum-based chemotherapy, improves the effects of anti-tumor drugs, and can be used for preparing drugs that can resist various tumors, such as lung cancer, ovarian cancer, prostate cancer, breast cancer, stomach cancer, nasopharyngeal cancer, esophageal cancer, malignant lymphoma, head and neck squamous cell carcinoma, thyroid cancer, osteosarcoma, etc.

The present invention provides antibodies useful as therapeutics for treating and / or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, hepatocellular cancer, colon cancer, pancreatic cancer, esophageal cancer, head & neck cancer, kidney cancer, in particular renal cell carcinoma, prostate cancer, liver cancer, melanoma, sarcoma, myeloma, neuroblastoma, placental choriocarcinoma, cervical cancer, and thyroid cancer, and the metastatic forms thereof. In one embodiment, the tumor disease is metastatic cancer in the lung.

The present invention discloses a medicine for preventing and curing carcinoma of esophagus and carcinoma of stomach with obvious therapeutic effect. It is made up by using 13 Chinese medicinal materials of isatis leaf, ganoderma, cordyceps, saffron, coptis root and others through a certain preparation process.

A Chinese medicine for helping the treatment of cancers, such as primary liver cancer, lung cancer and esophagus cancer, is prepared from 13 Chinese-medicinal materials including barbat skullcap, patrinia herb, zedoary, astragalus root, etc. Its advantage is high curative effect.

The invention discloses a traditional Chinese medicine composition for treating esophagus cancer. The traditional Chinese medicine composition mainly comprises pseudo-ginseng, solanum lyratum, hairyvein agrimony, edible tulip, rhizoma bletillae, oldenlandia diffusa, sculellaria barbata, asparagus cochinchinensis, rhizoma dioscoreae, flos sophorae, subprostrate sophora, rhizoma corydalis, bighead atractylodes rhizome, rhizoma curcumae longae and dried alum. The traditional Chinese medicine composition has a remarkable treatment effect for the esophagus cancer and has the effects of relieving pain, stopping bleeding and resisting cancers and tumors; the rhizoma dioscoreae in the prescription has a good opsonization effect for cancer patients subjected to chemoradiotherapy or operative treatment; and most of local common cheap herbs are selected and used, so that the economic burden on the patients is reduced.

The present invention relates to the use of a compound of formula 3 or a salt thereof to prepare a medicament or phototherapeutic agent for treating the following diseases, including: acne; AIDS; viral hepatitis; diabetic retinopathy; SARS virus infection; coronavirus Arterial stenosis; carotid artery stenosis; intermittent claudication; Asian (chicken) avian influenza virus infection; cervical dysplasia or various cancers, including: blood cancer, cervical cancer, nasopharyngeal cancer, tracheal cancer, laryngeal cancer, bronchial cancer , bronchiolar cancer, bladder cancer, esophageal cancer, stomach cancer, rectal cancer, colon cancer, prostate cancer, hollow organ cancer, bile duct cancer, urinary tract cancer, kidney cancer, uterine cancer, vaginal cancer and other gynecological adnexal cancer. The present invention also relates to methods of treating the above diseases. The present invention further relates to the use of the compound of formula 3 or a salt thereof to prepare a photodiagnostic agent for detecting the above-mentioned diseases and the following diseases, including: atherosclerosis, multiple sclerosis, diabetes, arthritis, rheumatism Arthritis, fungal infections, viral infections, chlamydial infections, bacterial infections, or parasitic diseases, HIV viral infections, hepatitis, herpes simplex, shingles, psoriasis, cardiovascular disease, and skin diseases. The present invention also relates to methods for detecting the above diseases using photodiagnostic agents. The present invention further relates to a method for low-temperature sterilization of surgical devices or other devices, including the steps of: providing a compound of Chemical Formula 3 or a salt thereof on the device; and subjecting the device to radiation treatment or sonication treatment. The invention further relates to a compound of formula 3 or a salt thereof linked or attached to a magnetic element. This compound acts as an MRI enhancer. The invention also relates to the use of such MRI enhancers for performing MRI scans.

The Chinese medicine composition for treating lung cancer, esophagus carcinoma and throat cancer is prepared with ginseng, pinellia tuber, fritillary bulb, bitter orange, ophiopogon root and other 19 kinds of Chinese medicinal materials in certain weight proportion. It has the functions of strengthening resistance to eliminate evil, restoring Qi and blood, balancing Yin-Yang, nourishing Yin to reduce pathogenic fire, etc so as to remit cancer symptoms, inhibit cancer cell growth and eliminate cancer. It has high curative effect and less toxic side effect.

The present invention relates to the field of gene related to carcinoma of esophagus, in particular, it relates to nucleotide sequence of gene-2(ECRG-2) related to carcinoma of esophagus. Said invention also relates to the recombinant carrier containing the described polynucleotide sequence and colibacillus containing said carrier. Said invention also further relates to the application of the esophagus carcinoma related gene-2 nucleotide sequence coded protein, and the growth speed of tumor cell transfected by said ECRG-2 polynucleotide sequence can be obviously reduced, and its death is increased.

Isolated peptides derived from SEQ ID NO: 21 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines, are described herein. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and / or CTL inducibility of the original sequences. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and / or compositions that include or incorporate any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors, including, for example, AML, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophagus cancer, gastric cancer, gastric diffuse-type cancer, lung cancer, lymphoma, prostate cancer, SCLC and soft tissue tumor.

The invention relates to a retinoid derivative and pharmaceutical composition and use thereof. The compound of the invention is capable of preventing or treating hematological tumours, such as acute leukemia, chronic leukemia, multiple myeloma and lymphoma, solid tumours, such as liver cancer, rectal cancer, mammary cancer and esophagus cancer, and skin disorders, such as psoriasis and acne.

The invention discloses a method for detecting the expression quantity of carcinoembryonic antigen mRNA and a special kit thereof. The kit comprises a primer pair: the sequence of one primer is shownby sequence 1 in a sequence table, and the sequence of the other primer is shown by sequence 2 in the sequence table. The kit and the method provided by the invention can be used for accurately quantifying the expression quantity of the carcinoembryonic antigen mRNA in tissue to be detected; and for instance, the invention can be used for carrying out qualitative and quantitative analysis on the expression situation of CEA mRNA in peripheral blood and bone marrow of tumor patients, and has important significance for judging the occurrence, the transfer, the recrudescence, the treatment effectevaluation and the dynamic observation of illness state of gastric cancer, esophagus cancer, colorectal cancer and rectal cancer. Experiment shows that the specificity of the detection method can reach 100% and the high sensitivity thereof can reach 100 copies / ml whole blood. Therefore, the invention plays an important role in the field of medical test.

The present invention relates to a Chinese medicine composition and its preparation process. In particular, it relates to a Chinese medicine prescription for curing the malignant tumor of digestive tract, including carcinoma of stomach, cardiac cancer, carcinoma of esophagus and rectal cancer, etc. and its preparation process. It can be made into dripping pills and soft capsule preparation.

The invention belongs to the field of medicinal chemistry, and particularly relates to phosphoglyceromutase 1. The invention provides an inhibitor of the phosphoglyceromutase 1; a specific structure is as shown in the formula I as shown in the description. The invention further provides a synthesis method of the structure as shown in the formula I as shown in the description and application in diseases related to cell apoptosis and tumors thereof; the diseases include various kinds of cancer of stomach cancer, liver cancer, myelomas, bladder cancer, prostatic cancer, breast cancer, rectal cancer, head and neck cancer, lung cancer, melanomas, ovarian cancer, cervical cancer, esophagus cancer and the like.

A temozolomide sustained release implant for treating solid tumors is characterized in that the sustained release implant includes effective dose of anticancer temozolomide, sustained release excipients and a certain quantity of sustained release moderator. Solid tumors include pancreatic cancer, lung cancer, liver cancer, breast cancer, cerebroma, ovarian cancer, prostatic carcinoma, esophageal carcinoma, lymphadenoma, osteosarcoma and colorectal cancer. Sustained release excipients mainly are one or combination of copolymer of glycolic acid and hydroxyacetic acid, polifeprosan, and poly(L-lactide-co-ethyl phosphate); in the process of decompression, temozolomide can be slowly released to local tumor, thus maintaining effective drug concentration of local tumor as well as significantly reducing overall toxic reaction. Being placed in local tumor, the sustained release implant not only reduces overall toxic reaction of temozolomide, but also selectively improves drug concentration in local tumor, enhancing the therapeutic effects of non-operative therapy such as chemotherapy drugs and radiotherapy.

The invention relates to a medicinal composition and method for preparation, wherein the medicinal composition is prepared from astragalus root, gen-seng, flavescent sophora root through supersonic extracting, alcohol depositing, water depositing, formulating, loading and freeze-drying. The composition can be used for treating primary liver cancer, lung carcinoma, esophagus cancer, restocarcinoma, malignant lymphoma, gynaecologic carcinoma, leucopenia and chronic hepatitis B.

The invention discloses a traditional Chinese medicine composition for treatment of cancers. The traditional Chinese medicine composition is prepared by medicinal materials of rhaphiolepis indica, podophyllum, gamboge, fructus camptothecae acuminatae, a wall snake, Artemisia apiacea, peppers, radix ophiopogonis, cynomorium songaricum, sealwort and the like. The traditional Chinese medicine composition has remarkable treatment effect on the various types of cancers of lung cancer, liver cancer, breast cancer, gastric cancer, lymph cancer, intestinal cancer, esophagus cancer, kidney cancer, bladder cancer, pancreatic cancer, melanoma, uterine cancer and the like.

The invention relates to the nucleic acid and polypeptide sequences of three novel human Ron-related gene variants (Ron-V1, Ron-V2, and Ron-V3). The invention also provides a process for producing the polypeptides of the variants, as well as uses for the nucleic acid, polypeptide and antibodies to same in diagnosing human breast carcinoma, breast adenocarcinoma, cervix epidermoid carcinoma, cervix epitheloid carcinoma, colon adenocarcinoma, urinary bladder carcinoma, prostate carcinoma, esophagus epidermoid carcinoma and esophagus carcinoma.

The present invention relates to siRNA field, and discloses the application of siRNA suppressing human Ezrin gene expression in the research on esophagus carcinoma cell proliferation. The present invention designs and synthesizes two pairs of siRNA's targeting human Ezrin gene, and constitutes the expression vector for them to express inside mammal cell successfully. These siRNA's can interfere the expression of Ezrin gene effectively and specifically, and esophagus carcinoma cell strain with lower Ezrin expression is established. The present invention lays foundation for the deep research on the function of Ezrin in esophagus carcinoma and other Ezrin related tumors. The present invention researches the relationship between Ezrin and the generation, development and cleaving proliferation of esophagus carcinoma, and lays foundation for revealing the pathogenesis of esophagus carcinoma and treating esophagus carcinoma.

The invention relates to a novel anti-tumor epirubicin compound being an epirubicin hydrochloride v-type compound, wherein the novel compound is easy to prepare and has advantages of less hygroscopicity, improved storage stability, good promotion of drug quality control and the like. The novel anti-tumor epirubicin compound is used for application in treatment and preventive drugs for treatment ofthe malignant lymphomam, breast cancer, lung cancer, soft tissue sarcoma, esophageal cancer, gastric cancer, liver cancer, pancreatic cancer, melanoma, colorectal cancer, ovarian cancer, multiple myeloma, leukemia, and brain glioma, treatment of the superficial bladder cancer and carcinoma in situ by the intravesical administration, and prevention of recurrence after transurethral resection and the like.

An irinotecan sustained release implant includes effective dose of anticancer irinotecan, sustained release excipients and a certain quantity of sustained release moderator. Solid tumors include pancreatic cancer, lung cancer, liver cancer, breast cancer, cerebroma, ovarian cancer, prostatic carcinoma, esophageal carcinoma, lymphadenoma, osteosarcoma and colorectal cancer. Sustained release excipients are mainly one or combination of copolymer of glycolic acid and hydroxyacetic acid, polifeprosan, poly(L-lactide-co-ethyl phosphate), and poly (L-lactide-co-phosphoric acid propyl); in the process of decompression, irinotecanpto can be slowly and steadily released to local tumor, thus maintaining effective drug concentration of local tumor as well as significantly reducing overall toxic reaction. Being placed in local tumor, the sustained release implant not only reduces overall toxic reaction of irinotecan, but also selectively improves drug concentration in local tumor, enhancing the therapeutic effects of non-operative therapy such as chemotherapy drugs and radiotherapy.